within Pharmacolibrary.Drugs.ATC.A;

model A10BD05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.009166666666666667,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 600,            
    Vdp             = 0.4,
    k12             = 1500,
    k21             = 1500
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Metformin and pioglitazone is a fixed-dose combination medication used in the management of type 2 diabetes mellitus to improve glycemic control. Metformin is a biguanide that decreases hepatic glucose production and increases peripheral glucose uptake, while pioglitazone is a thiazolidinedione that increases insulin sensitivity. This combination is approved and widely used currently for lowering blood sugar levels in patients with type 2 diabetes who require more than one oral antidiabetic agent.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects using known PK properties of metformin and pioglitazone administered together orally, as there is no published PK model for this specific fixed-dose combination product.</p><h4>References</h4><ol><li><p>Manitpisitkul, P, et al., &amp; Heald, D (2014). Pharmacokinetic interactions between topiramate and pioglitazone and metformin. <i>Epilepsy research</i> 108(9) 1519–1532. DOI:<a href=\"https://doi.org/10.1016/j.eplepsyres.2014.08.013\">10.1016/j.eplepsyres.2014.08.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25219351/\">https://pubmed.ncbi.nlm.nih.gov/25219351</a></p></li><li><p>Lyseng-Williamson, KA (2007). Sitagliptin. <i>Drugs</i> 67(4) 587–597. DOI:<a href=\"https://doi.org/10.2165/00003495-200767040-00007\">10.2165/00003495-200767040-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17352516/\">https://pubmed.ncbi.nlm.nih.gov/17352516</a></p></li><li><p>Karim, A, et al., &amp; Laurent, A (2007). Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. <i>Journal of clinical pharmacology</i> 47(1) 48–55. DOI:<a href=\"https://doi.org/10.1177/0091270006293756\">10.1177/0091270006293756</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17192501/\">https://pubmed.ncbi.nlm.nih.gov/17192501</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD05;
